McKesson saw its IBD SmartSelect Composite Rating rise to 96 Friday, up from 94 the day before.
The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
McKesson is trading about 2% above a 632.59 entry from a cup with handle.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The stock has an 86 EPS Rating, meaning its recent quarterly and annual earnings growth tops 86% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
The company reported a 4% increase in earnings for Q3. Revenue growth fell to 18%, down from 21% in the prior quarter.
McKesson holds the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
